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Abstract
 
Tumor necrosis factor 
 
a
 
 (TNF-
 
a
 
) is the key mediator of superantigen-induced T cell lethal
shock. Here, we show that nuclear factor of activated T cells transcription factor, NFATp,
controls susceptibility to superantigen-induced lethal shock in mice through its activation of
TNF-
 
a
 
 gene transcription. In NFATp-deficient mice, T cell stimulation leads to delayed in-
duction and attenuation of TNF-
 
a
 
 mRNA levels, decreased TNF-
 
a
 
 serum levels, and resis-
tance to superantigen-induced lethal shock. By contrast, after lipopolysaccharide (LPS) chal-
lenge, serum levels of TNF-
 
a
 
 and susceptibility to shock are unaffected. These results
demonstrate that NFATp is an essential activator of immediate early TNF-
 
a
 
 gene expression in
T cells and they present in vivo evidence of the inducer- and cell type–specific regulation of
TNF-
 
a
 
 gene expression. Furthermore, they suggest NFATp as a potential selective target in
the treatment of superantigen-induced lethal shock.
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Introduction
 
T cell production of TNF-
 
a
 
 is critical in a number of dis-
ease states, including superantigen-induced lethal shock. In
the case of toxic shock caused by staphylococcal entero-
toxin B (SEB), the superantigen directly binds MHC class
II and is recognized by V
 
b
 
8
 
1
 
 T cells in mice (1–5). In hu-
mans, it is recognized by V
 
b
 
3
 
1
 
, V
 
b
 
12
 
1
 
, V
 
b
 
14
 
1
 
, V
 
b
 
15
 
1
 
,
V
 
b
 
17
 
1
 
, and V
 
b
 
20
 
1
 
 T cells (for review see reference 6).
The subsequent burst of TNF-
 
a
 
 released by these T cells
initiates the cascade ultimately leading to cardiovascular
collapse and death (7). The lethal shock syndrome caused
by LPS stimulation of macrophages is also mediated by
TNF-
 
a
 
 (8, 9) and is phenotypically indistinguishable from
the superantigen-induced lethal shock syndrome (7).
 
TNF-
 
a
 
 gene expression in T cells stimulated through
the TCR is calcineurin dependent and is blocked by pre-
treatment of cells with the calcineurin inhibitor cy-
closporin A (CsA; references 10, 11). More recent studies
have shown that upon T cell activation the human TNF-
 
a
 
gene is regulated through the recruitment of nuclear factor
of activated T cells (NFAT) and ATF-2/Jun proteins to
their cognate binding sites in the TNF-
 
a
 
 enhancer com-
plex (12–14). However, regulation of TNF-
 
a
 
 by LPS in
macrophages results in the assembly of a different en-
hancer complex than is assembled in activated T cells. In
the case of LPS-stimulated TNF-
 
a
 
 gene expression, for-
mation of the enhancer complex does not include NFAT,
but rather is dependent upon the recruitment of Sp1 and
Ets proteins (15).
The NFAT family of transcription factors contains
five members (NFATp, NFATc, NFAT3, NFAT4, and
NFAT5; references 16–19), which are expressed in a tis-
sue-specific manner. NFATp, NFATc, and NFAT5 are
expressed in lymphoid tissues, whereas NFAT4, which is
abundant in skeletal muscle is only expressed in thymus,
and NFAT3 is not expressed in any lymphoid tissues (16,
19). NFAT proteins are translocated to the nucleus where
 
they participate in gene regulation upon a calcineurin-
mediated dephosphorylation step that can be blocked by
CsA (20, 21).
 
Here, using mice deficient in NFATp (NFATp
 
2/2
 
), we
demonstrate that NFATp is a critical and irreplaceable ac-
 
tivator of immediate early TNF-
 
a
 
 gene expression in T
cells. Furthermore, we show that NFATp controls suscep-
tibility to lethal shock caused by superantigen but not by
LPS. These studies thus provide in vivo evidence of the
stimulus- and cell type–specific transcriptional regulation
of the TNF-
 
a
 
 gene and identify the transcriptional mecha-
nism that influences the pathogenesis of lethal shock due
to superantigen.
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Materials and Methods
 
Animals.
 
Two pairs of NFATp
 
1/2
 
 mice (129Sv/J1 back-
ground backcrossed to Balb/c for seven generations; gift from
L.H. Glimcher (Harvard School of Public Health, Boston, MA)
were bred, and NFATp
 
2/2
 
 and wild-type (NFATp
 
1/1
 
) litter-
mates were genotyped by PCR as previously described (22).
Mice were maintained and bred in pathogen-free conditions and
were used for experiments at the age of 8–14 wk. Their care was
in accordance with institutional guidelines.
 
Cell Culture and Plasmids.
 
The Ar-5 T cell clone was main-
tained, transfected, and analyzed in the presence or absence of
CsA as previously described (10). Purified splenocytes were stim-
ulated in vitro at 1–3 x 10
 
7
 
 cells/ml with 1 
 
m
 
g/ml of plate-bound
anti-CD3 (2C11; PharMingen) for the indicated time points.
The 
 
2
 
982, 
 
2
 
475 and 
 
2
 
200 murine TNF-
 
a
 
 CAT reporter genes
have been described previously (10).
 
Electrophoretic Mobility Shift Assays and DNaseI Footprinting.
 
Nuclear extracts were prepared from splenocytes and the electro-
phoretic mobility shift assays were performed as previously de-
scribed (10). The sequence of the 
 
2
 
76 NFAT oligonucleotide is:
5
 
9
 
-AGGAAGTTTTCCGAGGGT-3
 
9
 
. The anti-NFATp anti-
body was a gift from Dr. A. Rao (Center for Blood Research,
Boston, MA) and the anti-NFATc antibody was purchased from
Affinity BioReagents, Inc.
DNaseI footprinting of the human TNF-
 
a
 
 promoter was per-
formed using recombinant NFATp (a gift from D. Thanos, Co-
lumbia University, New York, NY) as described previously (14).
 
RNase Protection Assay.
 
Cytokine mRNA levels were ana-
lyzed by multiprobe RNase Protection assay. RNA was hybrid-
ized overnight to 
 
32
 
P-labeled antisense RNA probes for TNF-
 
a
 
,
IL-2, IL-4, and L-32, which had been synthesized in vitro from
separate templates according to standard techniques (10).
 
Endotoxin and Superantigen Shock.
 
Female NFATp
 
2/2
 
 and
NFATp
 
1/1
 
 littermate mice were injected intraperitoneally with
D-Gal (D[
 
1
 
]-Galactosamine hydrochloride, G-1639; Sigma-
Aldrich) alone, D-Gal plus LPS (L-3012; Sigma-Aldrich), D-Gal
plus SEB (BT202; Toxin Technology Inc.), or D-Gal plus re-
combinant murine TNF-
 
a
 
 (13250-012; GIBCO BRL) solubi-
lized in 0.5 ml of pyrogen-free NaCl 0.9%. Control animals were
injected with the same volume of diluent. SEB was tested for LPS
contamination at Toxin Technology Inc. and was certified to be
LPS-free with the amount of LPS 
 
,
 
10–100 EU/mg of SEB (1.8
EU 
 
5 
 
1 ng LPS).
Lethal shock was determined on the basis of rough fur, respon-
siveness to cage motion, ataxia, and immobility. Mice were mon-
itored every 30 min after injection and were killed when they
were unresponsive to cage motion.
 
ELISA.
 
Serum cytokine levels were determined using Quan-
tikine M mouse TNF-
 
a
 
 and IL-2 ELISA kits from R&D Systems
according to the manufacturer’s instructions. Serum samples were
analyzed at a dilution of 1:5.
 
Results and Discussion
 
The Role of NFATp in Murine TNF-
 
a
 
 Gene Regulation.
 
To determine whether murine TNF-
 
a
 
 gene expression
was dependent upon NFAT proteins in activated T cells
similar to the human TNF-
 
a
 
 gene, we first determined the
minimal promoter region necessary for regulation of the
murine TNF-
 
a
 
 gene. We transfected murine TNF-
 
a
 
 CAT
reporter genes containing 
 
2
 
982, 
 
2
 
475, or 
 
2
 
200 nucle-
otides upstream of the TNF-
 
a
 
 mRNA cap site into a T cell
clone and stimulated the cells with anti-CD3 antibody in
the presence or absence of CsA. As shown in Fig. 1 A,
 
2
 
200 nucleotides upstream of the murine TNF-
 
a
 
 mRNA
cap site are sufficient for maximal anti-CD3 inducibility
and CsA sensitivity of the TNF-
 
a
 
 gene, similar to results
obtained using the human TNF promoter (10, 12).
There are six NFAT binding motifs with different affini-
ties for NFATp in the human TNF-
 
a
 
 promoter (Tsytsy-
kova, A.V., and A.E. Goldfeld, manuscript in preparation;
reference 14). To determine if the pattern of binding of
NFATp to corresponding sites in the murine TNF-
 
a
 
 pro-
moter was similar to its binding to the human TNF-
 
a
 
 pro-
moter, we next performed a quantitative DNAse I foot-
printing analysis. Using recombinant NFATp and a murine
TNF-
 
a
 
 promoter fragment spanning from 
 
2
 
200 to 
 
1
 
87
relative to the TNF-
 
a
 
 transcription start site, we detected
six sites in the murine TNF-
 
a
 
 promoter that bind NFATp
with different affinities (Fig. 1 B). Taken together, these
data suggested that NFATp plays a critical role in the regu-
lation of the murine TNF-
 
a
 
 gene in T cells similar to its
role in human TNF-
 
a
 
 gene regulation (10, 11, 23).
Previous studies have demonstrated that T cell–derived
TNF-
 
a
 
 is the key mediator of lethal shock caused by the
superantigen SEB (7). Antibodies to TNF-
 
a
 
 abrogate this
Figure 1. Murine TNF-a gene expres-
sion is dependent upon NFAT. (A) 2200
nucleotides upstream of the TNF-a mRNA
cap site are sufficient for CsA-sensitive anti-
CD3 induction of TNF-a in T cells. The
Ar-5 T cell clone was transfected with CAT
reporters linked to murine TNF-a promot-
ers containing 2200, 2475, or 2982 nu-
cleotides upstream of the mRNA cap site
and treated with anti-CD3 antibody and
pretreated with CsA for 10 min as indicated.
A representative CAT assay of three inde-
pendent transfections is shown. Transfec-
tions included CMV–b-gal as a control and
CAT activity was normalized to b-galac-
tosidase activity. (B) NFATp binds to six
sites in the TNF-a promoter. Quantitative
DNaseI footprinting using the murine
TNF-a promoter (2200 to 187 nucle-
otides relative to the transcription start site)
and increasing concentrations of recombi-
nant NFATp (100 ng, 400 ng, and 2 mg) or
BSA at 2 mg (–). The NFATp binding sites
and the ATF-2/Jun binding site (CRE) are
indicated in the drawing at the right. 
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syndrome, and SCID mice, which lack lymphocytes, are
resistant to shock, whereas SCID mice whose T cells have
been reconstituted are sensitive to shock caused by SEB (7).
Intriguingly, this cascade can be aborted by pretreatment of
mice with the calcineurin inhibitor CsA (7), suggesting a
role for calcineurin-dependent NFAT-driven TNF-
 
a
 
 gene
transcription in T cell lethal shock. Given that NFAT5 is
not calcineurin dependent (19), and given the restricted tis-
sue distribution of NFAT3 and NFAT4 (16), we specu-
lated that NFATp and/or NFATc might play a critical role
in the initial transcriptional events leading to superantigen-
induced lethal shock. To investigate this hypothesis we
next tested the effect of SEB challenge in NFATp
 
2/2
 
 mice
and their NFATp
 
1/1
 
 littermates because NFATc-deficient
mice are not viable (24, 25).
 
Mice Deficient in NFATp Are Resistant to Superantigen-
induced but Not to LPS-induced Lethal Shock.
 
We used the
well-characterized D-Gal–sensitized mouse model (26), to
evaluate the effect of SEB challenge in NFATp
 
2/2
 
 and
NFATp
 
1/1
 
 mice. Injection of 5 
 
m
 
g of SEB triggered a le-
thal shock syndrome in D-Gal–sensitized NFATp
 
1/1 but
not in D-Gal–sensitized NFATp2/2 mice (Table I). The
first signs of illness in NFATp1/1 mice became apparent 4 h
after injection of SEB and by 8–10 h after injection
NFATp1/1 mice became immobile and unresponsive and
were killed. Titration of SEB in the NFATp1/1 mice
showed 100 and 50% lethality with injection of 5 and 2 mg
of SEB, respectively (Table I). Strikingly, NFATp2/2 mice
showed very little or no signs of illness at all and completely
recovered within 24 h when injected with the same con-
centrations of SEB that caused death in their NFATp1/1
littermates. Thus, NFATp is a critical mediator in SEB-
induced lethal shock.
To demonstrate the specificity of the upstream signaling
events leading to TNF-a gene transcription and protein
production, and to demonstrate that this defect was not due
to an inability to respond to TNF-a in the NFATp2/2
mice, groups of D-Gal–sensitized NFAT1/1 and NFATp2/2
mice were injected with increasing amounts of recombinant
murine TNF-a protein. Both groups of mice had compara-
ble sensitivity to recombinant TNF-a with z50% lethality
at 0.1 mg/mouse (Table I). Thus, responsiveness to TNF-a
is not compromised in the NFATp2/2 mice.
LPS also causes a TNF-a–mediated lethal shock syn-
drome, which is phenotypically indistinguishable from
SEB-induced TNF-a–mediated lethal shock in the mouse
(7). By contrast to SEB, which triggers T cell secretion of
TNF-a, macrophages are the source of TNF-a in shock
caused by LPS (7). Notably, TNF-a gene regulation by
LPS in monocytes/macrophages is not dependent upon
NFAT and LPS-stimulated TNF-a mRNA levels from
NFATp1/1 and NFATp2/2 splenocytes are equivalent (15).
Consistent with this observation, LPS triggered an identical
lethal shock syndrome in both NFATp1/1 and NFATp2/2
D-Gal–sensitized mice with 100 and 67% lethality at 1 and
0.1 mg of LPS, respectively (Table I). Thus, NFATp2/2
mice are sensitive to LPS-mediated lethal shock in contrast
to their resistance to SEB-induced lethal shock.
Decreased TNF-a Serum Levels in NFATp2/2 Mice after
SEB Challenge. We next measured serum levels of TNF-a
in NFATp1/1 and NFATp2/2 mice after injection with
SEB (5 mg/mouse) or LPS (1 mg/mouse). As shown in Fig.
2, TNF-a levels in NFATp1/1 mice peak between 1 and
2 h after injection with SEB or LPS and decrease sharply at
later time points. However, after injection of NFATp2/2
mice with SEB, the levels of TNF-a protein are markedly
decreased (approximately fivefold) as compared with those
levels obtained in NFATp1/1 littermates (Fig. 2 A). By
contrast, serum TNF-a levels from NFATp1/1 and
NFATp2/2 animals injected with LPS are virtually identical
(Fig. 2 B). Taken together, our results indicate that
NFATp2/2 mice are resistant to otherwise lethal doses of
SEB due to dramatically decreased TNF-a production by
SEB-responsive T cells.
Notably, increasing amounts of SEB caused death in
NFATp2/2 mice, achieving 100% lethality with the injec-
tion of 100 mg (Table I). We next measured serum TNF-a
levels in mice injected with 10 and 100 mg of SEB. TNF-a
levels increase in both genotypes in a SEB dose-dependent
manner, but stay dramatically lower in knockout animals as
compared with their NFATp1/1 littermates (Fig. 2 C). As a
control for the specificity of this effect upon TNF-a, we
measured IL-2 levels after injection of a lethal dose of SEB
in NFATp2/2 mice and NFATp1/1 littermates and found
Table I. NFATp2/2 Mice Are Resistant to SEB-induced T Cell–
mediated Lethal Shock, but Not to LPS-stimulated Lethal Shock
D-Gal LPS SEB TNF-a Lethality
NFATp1/1 NFATp2/2
mg/mouse mg/mouse dead/total
20 – – – 0/3
– 100 – – 0/3
20 10 – – 5/5 5/5
20 1 – – 5/5 3/3
20 0.1 – – 8/12 6/9
20 0.01 – – 0/3 0/3
– – 200 – 0/3
– – 100 – 0/3
20 – 100 – 3/3 3/3
20 – 10 – 4/4 3/4
20 – 5 – 14/14 0/9
20 – 2 – 4/7 0/6
– – – 1 0/3 0/3
20 – – 1 4/4 4/4
20 – – 0.1 3/6 4/6
20 – – 0.01 0/6 0/6
Female mice received the indicated dosage of D-Gal, LPS, SEB, or
recombinant murine TNF-a intraperitoneally in 0.5 ml pyrogen-free
0.9% NaCl. Surviving mice were monitored for 1 wk after injection.
None of the mice that survived for 24 h after injection died later.584 NFATp Controls Superantigen Toxic Shock
no difference (Fig. 2 D). Thus, NFATp2/2 mice are signif-
icantly compromised in their ability to produce TNF-a af-
ter SEB challenge at all doses; however, at higher doses of
SEB the threshold lethal level of TNF-a (Fig. 2 C, dotted
line) is achieved in NFATp2/2 animals.
Delayed Induction of TNF-a mRNA Levels in Splenic T
Cells from NFATp2/2 Mice. TNF-a is one of the earliest
genes transcribed in an activated murine T cell (10). We
thus speculated that NFATp plays a unique role as a tran-
scriptional activator in immediate early TNF-a gene ex-
pression in activated T cells. As shown in Fig. 3 A, the ki-
netics of induction of TNF-a mRNA levels in NFATp2/2
T cells are delayed z2 h compared with NFATp1/1 T cells
(compare lanes 1–4 to lanes 7–10). Furthermore, these lev-
els remain lower (z50%) than those in NFATp1/1 mice
for the first 8 h after stimulation (Fig. 3 A) and become
equivalently low at 21 h after induction (Fig. 2 B, compare
lane 3 to lane 7). As a control we measured IL-2 and IL-4
mRNA levels and found that the kinetics of induction of
mRNA for both of these genes was similar in both geno-
types (Fig. 3 A). Although IL-4 mRNA levels in NFATp2/2
T cells were initially relatively lower (at 2 h), they were
increased at all other timepoints compared with NFATp1/1
levels (Fig. 2, A and B), consistent with previous reports
(27). We conclude that the immediate early induction of
TNF-a gene expression and the achievement of maximal
mRNA levels in activated T cells requires NFATp.
The Absence of NFATp Binding Does Not Affect Binding of
NFATc to the TNF-a Promoter. We next investigated
whether binding of NFATc was affected in the NFATp2/2
mice and performed electrophoretic mobility shift assays
using nuclear extracts from unstimulated or anti-CD3–acti-
vated splenocytes derived from NFATp2/2 and NFATp1/1
littermate mice using the high affinity TNF-a 276 NFAT
Figure 2. TNF-a protein levels are reduced in NFATp2/2 mice after
SEB but not after LPS injection.  At each time point after injection with
SEB (A, C, D) or LPS (B) two NFATp1/1 (r) and two NFATp2/2 (e)
mice were killed and serum TNF-a (A, B, C) or IL-2 (D) levels were eval-
uated by ELISA. The error bars represent standard deviation. *P , 0.02 for
protein levels in NFATp2/2 mice versus their NFATp1/1 littermates.
Figure 3. Kinetics of induction of
cytokine mRNAs during primary in
vitro stimulation of NFATp1/1 and
NFATp2/2 splenocytes. (A and B)
The kinetics of induction of TNF-a
by anti-CD3 are delayed in
NFATp2/2 mice. Spleen cells iso-
lated from NFATp1/1 ( 1/1) and
NFAT2/2 (2/2) mice were unstim-
ulated (UN) or stimulated up to 45 h
with plate-bound anti-CD3 as indi-
cated. At the indicated times, cells
were harvested and the total cellular RNA was analyzed for TNF-a, IL-4,
IL-2, and L-32 mRNA levels by RNase Protection assay. (C) Lack of bind-
ing of NFATp to DNA in NFATp2/2 splenocytes. Nuclear extracts were
prepared from purified splenocytes from NFATp1/1 (1/1) and NFAT2/2
(2/2) mice that were unstimulated (UN) or stimulated with plate-bound
anti-CD3 antibody for 1 h. An oligonucleotide probe matching the 276
NFAT binding site was used and the binding assay was performed in the
presence or absence of the NFATp or NFATc antibodies as indicated.585 Tsytsykova and Goldfeld Brief Definitive Report
site as a probe. As shown in Fig. 3 C, NFATc binding is
not affected in NFATp2/2 splenocytes. Furthermore, we
examined the kinetics of NFATc binding to the 276
NFAT site up to 48 h after anti-CD3 induction in both
NFATp1/1 and NFATp2/2 mice and found no difference
(data not shown). Thus, the absence of NFATp does not
impair NFATc binding to the TNF-a promoter.
Lethal shock in D-Gal sensitized mice is characterized by
fulminant hepatitis (7, 26). We next performed histopatho-
logical analysis of livers taken from treated animals 8 h after
D-Gal, SEB plus D-Gal, or TNF-a plus D-Gal administra-
tion. As shown in Fig. 4, sections from livers taken from
NFATp1/1 mice coinjected with D-Gal and SEB (5 mg)
showed signs of fulminant hepatitis with massive hemor-
rhage and hepatocyte death with swelling of the cytoplasm
and loss of nuclei. By contrast, sections from livers of
NFATp2/2 mice injected with the same dose of D-Gal and
SEB showed only signs of nonspecific hepatotoxicity com-
parable to sections from mice injected with D-Gal alone or
mice given no injection (Fig. 4). Liver sections from both
NFATp1/1 and NFATp2/2 mice treated with TNF-a and
D-Gal showed identical damage consistent with fulmi-
nant hepatitis and massive hemorrhage and cell death (Fig.
4). Taken together, the SEB unresponsiveness of the
NFATp2/2 mice is not due to impairment of the TNF-a
signaling pathway.
The TNF-a gene is a unique example of a gene that is
regulated through the assembly of inducer- and cell type–
specific enhancer complexes (12, 14, 15). In the case of T
cells activated through the TCR or by calcium flux, in vivo
recruitment of NFATp is correlated with TNF-a gene ex-
pression (10, 12, 23). Our studies using NFATp2/2 mice
demonstrate that NFATp cannot be replaced by another
NFAT family member in the TNF-a enhancer in activated
T cells. Although the NFAT family of proteins share a rel-
like DNA binding domain, the transcriptional activation do-
mains of these proteins are distinct (16, 19). Thus, it is likely
that in the initial induction of TNF-a transcription, NFATp
uniquely interacts with the other components in the TNF-a
enhancer complex assembled in activated T cells.
NFATp2/2 mice remain sensitive to LPS-mediated lethal
shock consistent with the observation that LPS-stimulated
TNF-a gene expression is not impaired in splenocytes
from NFATp2/2 mice, and that NFATp is not recruited to
the LPS-stimulated TNF-a enhancer in macrophages (15).
These results present in vivo evidence of the inducer- and
cell type–specific regulation of TNF-a gene expression
that has previously been established in cell culture and in in
vitro model systems (12–14).
To our knowledge, NFATp is the first transcription fac-
tor to be identified that controls susceptibility to superanti-
gen-induced lethal shock through its activation of imme-
diate early TNF-a gene transcription. Therapeutic
approaches that globally inhibit TNF-a have been limited
by their lack of specificity (28, 29). The results presented
here demonstrate that through the manipulation of the cell
type– and inducer-specific assembly of TNF-a enhancer
complexes, TNF-a can be selectively inhibited and disease
outcome can be dramatically influenced. Moreover, sus-
ceptibility or resistance to disease where TNF-a plays a
role may be directly linked to the presence or the levels of
expression of a single transcription factor.
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Figure 4. Histological analysis of liver sections after superantigen or
TNF-a challenge. Liver was removed from NFATp1/1 and NFATp2/2
mice 8 h after intraperitoneal injection of 0.9% NaCl (nil), D-Gal (20
mg), SEB (5 mg) plus D-Gal, or recombinant TNF-a (1 mg) plus D-Gal
as indicated. Tissues were directly transferred into 10% formalin solution.
Sections were stained with hematoxylin and eosin. Original magnifica-
tion: approximately 3100.586 NFATp Controls Superantigen Toxic Shock
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